Does the media favor BEAM or PRME?

In the previous week, Beam Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for Beam Therapeutics and 2 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Beam Therapeutics' score of 0.71 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ZLAB or PRME?

Zai Lab has higher revenue and earnings than Prime Medicine. Zai Lab is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 4.21 -$175.54M -$1.62 N/A Prime Medicine $4.63M 132.64 -$201.14M -$1.23 N/A

Is ZLAB or PRME more profitable?

Zai Lab has a net margin of -39.29% compared to Prime Medicine's net margin of -4,917.55%. Zai Lab's return on equity of -24.32% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -39.29% -24.32% -15.52% Prime Medicine -4,917.55% -188.82% -60.97%

Does the media prefer ZLAB or PRME?

In the previous week, Zai Lab had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for Zai Lab and 2 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Zai Lab's score of 0.93 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PRME or HCM?

HUTCHMED has higher revenue and earnings than Prime Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prime Medicine $4.63M 132.64 -$201.14M -$1.23 N/A HUTCHMED $548.51M 3.63 $456.91M N/A N/A

Does the media prefer PRME or BHC?

In the previous week, Bausch Health Cos had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for Bausch Health Cos and 2 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Bausch Health Cos' score of 0.20 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Prime Medicine (PRME) Competitors

$3.40 -0.15 (-4.23%)

Closing price 06/1/2026 04:00 PM Eastern

Extended Trading

$3.38 -0.02 (-0.59%)

As of 06/1/2026 06:35 PM Eastern

Compare

PRME vs. BEAM, ZLAB, HCM, BHC, and TRVI

Should you buy Prime Medicine stock or one of its competitors? MarketBeat compares Prime Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prime Medicine include Beam Therapeutics (BEAM), Zai Lab (ZLAB), HUTCHMED (HCM), Bausch Health Cos (BHC), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.

How does Prime Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Beam Therapeutics has a net margin of -39.66% compared to Prime Medicine's net margin of -4,917.55%. Beam Therapeutics' return on equity of -29.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.93	-$79.99M	-$0.68	N/A
Prime Medicine	$4.63M	132.64	-$201.14M	-$1.23	N/A

Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

In the previous week, Beam Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for Beam Therapeutics and 2 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Beam Therapeutics' score of 0.71 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics currently has a consensus price target of $46.83, indicating a potential upside of 50.40%. Prime Medicine has a consensus price target of $7.65, indicating a potential upside of 125.00%. Given Prime Medicine's higher possible upside, analysts clearly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Beam Therapeutics beats Prime Medicine on 10 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Zai Lab has a net margin of -39.29% compared to Prime Medicine's net margin of -4,917.55%. Zai Lab's return on equity of -24.32% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Zai Lab has higher revenue and earnings than Prime Medicine. Zai Lab is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.21	-$175.54M	-$1.62	N/A
Prime Medicine	$4.63M	132.64	-$201.14M	-$1.23	N/A

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zai Lab presently has a consensus target price of $45.83, suggesting a potential upside of 168.19%. Prime Medicine has a consensus target price of $7.65, suggesting a potential upside of 125.00%. Given Zai Lab's higher possible upside, research analysts clearly believe Zai Lab is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Zai Lab had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for Zai Lab and 2 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Zai Lab's score of 0.93 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market.

Summary

Zai Lab and Prime Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to HUTCHMED?

Prime Medicine (NASDAQ:PRME) and HUTCHMED (NASDAQ:HCM) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

HUTCHMED has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. HUTCHMED's return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
HUTCHMED	N/A	N/A	N/A

HUTCHMED has higher revenue and earnings than Prime Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	132.64	-$201.14M	-$1.23	N/A
HUTCHMED	$548.51M	3.63	$456.91M	N/A	N/A

In the previous week, Prime Medicine had 1 more articles in the media than HUTCHMED. MarketBeat recorded 2 mentions for Prime Medicine and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.87 beat Prime Medicine's score of 0.94 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Overall Sentiment
Prime Medicine	Positive
HUTCHMED	Very Positive

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Prime Medicine currently has a consensus price target of $7.65, suggesting a potential upside of 125.00%. HUTCHMED has a consensus price target of $16.80, suggesting a potential upside of 47.37%. Given Prime Medicine's stronger consensus rating and higher probable upside, research analysts clearly believe Prime Medicine is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Prime Medicine beats HUTCHMED on 8 of the 14 factors compared between the two stocks.

How does Prime Medicine compare to Bausch Health Cos?

Prime Medicine (NASDAQ:PRME) and Bausch Health Cos (NYSE:BHC) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Bausch Health Cos has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	132.64	-$201.14M	-$1.23	N/A
Bausch Health Cos	$10.53B	0.19	$157M	-$3.24	N/A

Bausch Health Cos has a net margin of -11.47% compared to Prime Medicine's net margin of -4,917.55%. Prime Medicine's return on equity of -188.82% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Bausch Health Cos had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for Bausch Health Cos and 2 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Bausch Health Cos' score of 0.20 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prime Medicine has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Prime Medicine currently has a consensus price target of $7.65, suggesting a potential upside of 125.00%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 50.52%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities analysts clearly believe Prime Medicine is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Prime Medicine beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

How does Prime Medicine compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Trevi Therapeutics currently has a consensus price target of $22.90, indicating a potential upside of 64.16%. Prime Medicine has a consensus price target of $7.65, indicating a potential upside of 125.00%. Given Prime Medicine's higher possible upside, analysts clearly believe Prime Medicine is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Trevi Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

In the previous week, Prime Medicine had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 2 mentions for Prime Medicine and 1 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.89 beat Prime Medicine's score of 0.94 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Trevi Therapeutics	Very Positive
Prime Medicine	Positive

Trevi Therapeutics has higher earnings, but lower revenue than Prime Medicine. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Prime Medicine	$4.63M	132.64	-$201.14M	-$1.23	N/A

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Trevi Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Trevi Therapeutics' return on equity of -24.53% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Summary

Trevi Therapeutics beats Prime Medicine on 11 of the 16 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRME vs. The Competition

Export

Metric	Prime Medicine	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$641.19M	$459.80M	$4.38B	$12.56B
Dividend Yield	N/A	N/A	6.84%	5.30%
P/E Ratio	-2.76	N/A	21.74	26.63
Price / Sales	132.64	335.47	205.21	112.54
Price / Cash	N/A	N/A	57.52	37.60
Price / Book	5.07	2.78	33.85	6.88
Net Income	-$201.14M	-$81.71M	$111.12M	$336.73M
7 Day Performance	14.48%	3.42%	2.06%	3.07%
1 Month Performance	-0.29%	1.48%	5.97%	7.13%
1 Year Performance	N/A	N/A	17.37%	38.42%

Prime Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRME Prime Medicine	1.9311 of 5 stars	$3.40 -4.2%	$7.65 +125.0%	N/A	$641.19M	$4.63M	N/A	N/A
BEAM Beam Therapeutics	2.1212 of 5 stars	$29.79 +4.0%	$46.83 +57.2%	+97.8%	$2.95B	$164.01M	N/A	510	Gap Down
ZLAB Zai Lab	3.42 of 5 stars	$18.45 -0.9%	$45.83 +148.4%	-43.6%	$2.11B	$460.16M	N/A	1,784
HCM HUTCHMED	3.9813 of 5 stars	$11.75 -2.0%	$16.88 +43.6%	-17.2%	$2.09B	$548.51M	N/A	1,796
BHC Bausch Health Cos	3.0805 of 5 stars	$5.39 -1.5%	$8.00 +48.4%	+17.3%	$2.04B	$10.53B	N/A	20,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRME) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prime Medicine (PRME) Competitors

PRME vs. BEAM, ZLAB, HCM, BHC, and TRVI

How does Prime Medicine compare to Beam Therapeutics?

Summary

How does Prime Medicine compare to Zai Lab?

Summary

How does Prime Medicine compare to HUTCHMED?

Summary

How does Prime Medicine compare to Bausch Health Cos?

Summary

How does Prime Medicine compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prime Medicine (PRME) Competitors

PRME vs. BEAM, ZLAB, HCM, BHC, and TRVI

How does Prime Medicine compare to Beam Therapeutics?

Is BEAM or PRME more profitable?

Which has higher valuation & earnings, BEAM or PRME?

Which has more risk and volatility, BEAM or PRME?

Does the media favor BEAM or PRME?

Do analysts prefer BEAM or PRME?

Do insiders & institutionals have more ownership in BEAM or PRME?

Summary

How does Prime Medicine compare to Zai Lab?

Is ZLAB or PRME more profitable?

Which has stronger valuation & earnings, ZLAB or PRME?

Do insiders & institutionals hold more shares of ZLAB or PRME?

Do analysts rate ZLAB or PRME?

Does the media prefer ZLAB or PRME?

Which has more volatility & risk, ZLAB or PRME?

Summary

How does Prime Medicine compare to HUTCHMED?

Is PRME or HCM more profitable?

Which has stronger valuation and earnings, PRME or HCM?

Does the media refer more to PRME or HCM?

Do insiders & institutionals have more ownership in PRME or HCM?

Which has more risk & volatility, PRME or HCM?

Do analysts rate PRME or HCM?

Summary

How does Prime Medicine compare to Bausch Health Cos?

Which has higher valuation & earnings, PRME or BHC?

Is PRME or BHC more profitable?

Do institutionals & insiders have more ownership in PRME or BHC?

Does the media prefer PRME or BHC?

Which has more volatility and risk, PRME or BHC?

Do analysts recommend PRME or BHC?

Summary

How does Prime Medicine compare to Trevi Therapeutics?

Do analysts prefer TRVI or PRME?

Which has more risk & volatility, TRVI or PRME?

Does the media favor TRVI or PRME?

Which has higher valuation & earnings, TRVI or PRME?

Do institutionals & insiders believe in TRVI or PRME?

Is TRVI or PRME more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools